Skip to main content

Table 1 Clinical parameters of the subjects used for HBV sequencing

From: Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients

whole HBV sequencing    
  HCC group 1 non-HCC group 1  
  (n = 37) (n = 38)  
Age (Years) 37 ± 10.0 38 ± 11.6  
Sex:Male 29 (78%) 28 (73%)  
HBV-DNA (log/ml) 5.5 ± 1.1 5.2 ± 0.9  
HBeAg positive 20 (54%) 20 (52%)  
Platelet (× 104/μl) 11.4 ± 5.3 16.4 ± 6.0  
Total Bilirubin (mg/dl) 1.3 ± 1.1 1.6 ± 1.97  
Albumin (g/dl) 3.58 ± 0.8 4.0 ± 0.44  
core promoter sequencing    
  HCC group 2 non-HCC group 2 pre-HCC group 2
  (n = 40) (n = 52) (n = 16)
Age (Years) 54 ± 13.1 38 ± 11.4*# 48 ± 10.2
Sex:Male 78% 83% 94% *
HBV-DNA (log/ml) 5.76 ± 2.04 7.23 ± 1.37* 6.42 ± 1.66
HBeAg positive 55% 75% 79%
Platelet (× 104/μl) 12.1 ± 6.39 17.1 ± 7.15* 15.0 ± 6.59
Total Bilirubin (mg/dl) 1.32 ± 1.13 1.29 ± 2.07 2.55 ± 6.66
Albumin (g/dl) 3.58 ± 0.84 4.10 ± 0.51* 3.84 ± 0.57
  1. *p < 0.05 vs. HCC group 2, #p < 0.05 vs. pre-HCC group 2